Pharmacogenetics/pharmacogenomics and antirheumatic drugs in rheumatology

被引:5
作者
Ferraccioli, G [1 ]
De Santis, M [1 ]
Tolusso, B [1 ]
机构
[1] Univ Cattolica Sacro Cuore, CIC, Div Rheumatol, Postgrad Sch Rheumatol,Inst Internal Med & Geriat, I-00168 Rome, Italy
关键词
azathioprine; COXIBs; cyclophosphamide; leflunomide; methotrexate; NSAIDs; pharmacogenetic; pharmacogenomics; rituxan; SNP; TNF-alpha blockers;
D O I
10.1517/14622416.5.8.1107
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Genomic medicine has raised many expectations with regard to individualized therapies. Drug response is a complex function of many genes interacting with environmental and behavioral factors. In addition, poor prescribing, interactions between drugs and an incomplete understanding of the metabolism of many drugs, which are administered simultaneously to treat concomitant morbidities, are leading causes of the occurrence of adverse drug reactions in chronic non-inflammatory and autoimmune rheumatic diseases. Symptomatic non-steroidal anti-inflammatory drugs, as well as disease-modifying drugs, are complicated by drop-outs (poor patient compliance) in a large percentage of patients. Even though intensive and careful monitoring is always clearly advisable, preliminary data suggest that typing of genes controlling the effects, metabolism and response of drugs might be of clinical utility to define the 'at-risk' genotype.
引用
收藏
页码:1107 / 1116
页数:10
相关论文
共 72 条
[1]   METHOTREXATE IN RHEUMATOID-ARTHRITIS - TOXIC EFFECTS AS THE MAJOR FACTOR IN LIMITING LONG-TERM TREATMENT [J].
ALARCON, GS ;
TRACY, IC ;
BLACKBURN, WD .
ARTHRITIS AND RHEUMATISM, 1989, 32 (06) :671-676
[2]   B cell depletion therapy in systemic lupus erythematosus. [J].
Jennifer Anolik ;
Iñaki Sanz ;
R. John Looney .
Current Rheumatology Reports, 2003, 5 (5) :350-356
[3]   INCIDENCE OF ADVERSE DRUG EVENTS AND POTENTIAL ADVERSE DRUG EVENTS - IMPLICATIONS FOR PREVENTION [J].
BATES, DW ;
CULLEN, DJ ;
LAIRD, N ;
PETERSEN, LA ;
SMALL, SD ;
SERVI, D ;
LAFFEL, G ;
SWEITZER, BJ ;
SHEA, BF ;
HALLISEY, R ;
VANDERVLIET, M ;
NEMESKAL, R ;
LEAPE, LL .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1995, 274 (01) :29-34
[4]   A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis [J].
Bathon, JM ;
Martin, RW ;
Fleischmann, RM ;
Tesser, JR ;
Schiff, MH ;
Keystone, EC ;
Genovese, MC ;
Wasko, MC ;
Moreland, LW ;
Weaver, AL ;
Markenson, J ;
Finck, BK .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (22) :1586-1593
[5]   Predicting disease using genomics [J].
Bell, J .
NATURE, 2004, 429 (6990) :453-456
[6]   Is there a place for leflunomide in the treatment of rheumatoid arthritis? [J].
Breedveld, FC .
LANCET, 2001, 358 (9289) :1198-1200
[7]   Genetic markers of treatment response in rheumatoid arthritis [J].
Bridges, SL .
ARTHRITIS AND RHEUMATISM, 2004, 50 (04) :1019-1022
[8]  
Busauschina A, 2004, TRANSPL P, V36, p229S, DOI 10.1016/j.transproceed.2004.01.021
[9]  
Cameron JS, 1999, J AM SOC NEPHROL, V10, P413
[10]   Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene [J].
Cartron, G ;
Dacheux, L ;
Salles, G ;
Solal-Celigny, P ;
Bardos, P ;
Colombat, P ;
Watier, H .
BLOOD, 2002, 99 (03) :754-758